ClinicalTrials.gg
Active, not recruitingNCT04404283ECHELON-3Updated Oct 21, 2026Results posted

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

A Phase 3 interventional study of Brentuximab vedotin and Rituximab in Diffuse Large B-cell Lymphoma, sponsored by Seagen, a wholly owned subsidiary of Pfizer. Active, not recruiting at 143 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Seagen, a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Treatment

Updated Oct 21, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies in Lymphoma, Large B-Cell, Diffuse by Pfizer — none open to participants now, 1 under way, 1 of them phase 3. Lymphoma, Large B-Cell, Diffuse · Pfizer.

Enrollment
2nd of 25
240 · median 58
Started
2020
with 1 other
Phase 3
3 of 25
none open now
Registered
20th of 25
by date

Among the 25 studies in Lymphoma, Large B-Cell, Diffuse by Pfizer, this one is the 2nd largest by enrollment, is one of 2 that started in 2020, is one of 3 in phase 3, and was the 20th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

None of the 25 studies in Lymphoma, Large B-Cell, Diffuse by Pfizer is open now. The open studies under Lymphoma, Large B-Cell, Diffuse, anywhere →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 25 studies in Lymphoma, Large B-Cell, Diffuse by Pfizer as a file.
02

Study summary

Participants in this study will have diffuse large B-cell lymphoma (DLBCL) that has come back or not gotten better with treatment. The trial will study whether brentuximab vedotin plus two drugs works better to treat this type of cancer than the two drugs alone.

Participants will be randomly assigned to get either brentuximab vedotin or placebo. The placebo will look like brentuximab vedotin, but has no medicine in it. Since the study is "blinded," participants and their doctors will not know whether a participant gets brentuximab vedotin or placebo. All participants in the study will get rituximab and lenalidomide. These are drugs that can be used to treat DLBCL.

03

Conditions studied

  • Diffuse Large B-cell Lymphoma

Keywords

  • Seattle Genetics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with diffuse and transformed large B-cell lymphoma (R/R DLBCL). DLBCL and cell of origin (GCB versus non-GCB) will be histologically determined by local pathology assessment for the purposes of study eligibility and stratification.
  • Participants must have R/R disease following 2 or more lines of prior systemic therapy.

    • For participants with transformed DLBCL, at least the last systemic therapy used must have been for DLBCL
  • Participants must be or CAR-T ineligible according to the investigator and must meet at least one of the following criteria:

    1. One or more co-morbidities, including cardiac, pulmonary, renal or hepatic dysfunction that in the opinion of the Investigator make the participant medically unfit to received HSCT or CAR-T therapy
    2. Active disease following induction and salvage chemotherapy
    3. Inadequate stem cell mobilization (for HSCT)
    4. Relapse following prior HSCT or CAR-T
    5. Unable to receive CAR-T therapy due to financial, geographic, insurance, or manufacturing issues
  • Participants must have tumor tissue submitted to the central pathology lab. The tumor tissue submitted should be from the most recent that contains DLBCL.
  • An (ECOG) performance status score of 0 to 2
  • Participants must have fluorodeoxyglucose (FDG)-avid disease by positron emission tomography (PET) and bidimensional of at least 1.5 cm by computed tomography (CT), as assessed by the site radiologist within 28 days of Day 1.

Exclusion criteria

Exclusion Criteria:

  • History of another within 2 years before the first dose of study drug or any evidence of residual disease from a previously diagnosed malignancy
  • History of progressive multifocal leukoencephalopathy (PML)
  • Active cerebral/meningeal disease related to the underlying malignancy. Participants with a history of cerebral/meningeal disease related to the underlying malignancy are allowed if prior CNS disease has been effectively treated and without progression for at least 3 months.
  • Any uncontrolled Grade 3 or higher (per version 5.0) viral, bacterial, or fungal infection within 2 weeks prior to the first dose of study drug. Routine antimicrobial prophylaxis is permitted
  • Chemotherapy, radiotherapy, biologics, and/or other antitumor treatment with immunotherapy that is not completed 3 weeks prior to first dose of study drug, unless underlying disease has progressed on treatment
  • Previous treatment with brentuximab vedotin or lenalidomide.

    • Previous treatment with other vedotin-based ADCs is permitted if the last dose is at least 6 months prior to Day 1.
  • Current therapy with medications (including ), other systemic anti-neoplastic, or agents

    a) Prednisone (or equivalent) ≤10 mg/day may be used for non-lymphomatous purposes

  • Documented history of a cerebral vascular event (stroke or ), unstable angina, myocardial infarction, or cardiac symptoms consistent with (NYHA) Class III-IV within 6 months prior to the first dose of study drugs
  • Congestive heart failure, Class III or IV, by the NYHA criteria
  • Grade 2 or higher peripheral sensory or motor neuropathy at baseline
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
240 participants (actual)

Study arms

  • Experimental
    Experimental Arm

    Brentuximab vedotin + lenalidomide + rituximab

    Drug: Brentuximab vedotin · Drug: Rituximab · Drug: Lenalidomide

  • Active comparator
    Control Arm

    Placebo + lenalidomide + rituximab

    Drug: Rituximab · Drug: Lenalidomide · Other: Placebo

Interventions

  • 1.2 mg/kg administered into the vein (IV; intravenously) infusion every 3 weeks

  • 375 mg/m\^2 administered via intravenous infusion on Cycle 1 Day 1. 1400 mg injected under the skin (subcutaneous) permitted every 3 weeks from Cycle 2 Day 1 through end of treatment.

  • 20 mg given by mouth (orally) daily

  • OtherPlacebo

    Administered via intravenous infusion every 3 weeks

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from the date of randomization to the date of death due to any cause. Participants who had not died were censored at the last known alive date or the data cutoff date, whichever was earlier. OS was estimated using the Kaplan-Meier method.

    Time frame: From the date of randomization until date of death or censoring date, whichever occurred first (maximum up to 50 months)

Secondary outcomes

  1. Progression-Free Survival (PFS) as Assessed by Investigator Per Lugano 2014

    PFS was defined as the time from the date of randomization to the date of first documentation of progressive disease (PD) or to death due to any cause, whichever occurred first, based on the investigator assessment of tumor response according to the criteria defined by the Lugano Classification, 2014.

    Time frame: From date of randomization until the first documentation of PD or to death due to any cause, whichever occurred first (maximum up to 50 months)

  2. Objective Response Rate (ORR) as Assessed by Investigator Per Lugano 2014

    ORR per Lugano 2014 by investigator was defined as the percentage of participants with a response assessment of complete response (CR) or partial response (PR) per the Lugano 2014 response criteria as assessed by the investigator.

    Time frame: From the date of randomization until PD or initiation of new anticancer therapy (maximum up to 50 months)

  3. Complete Response (CR) Rate as Assessed by Investigator Per Lugano 2014

    CR rate per Lugano 2014 by investigator was defined as the percentage of participants with a best response of CR per the Lugano 2014 response criteria as assessed by the investigator.

    Time frame: From the date of randomization until PD or initiation of new anticancer therapy (maximum up to 50 months)

  4. Duration of Response (DOR) as Assessed by Investigator Per Lugano 2014

    DOR was defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of tumor progression per the Lugano 2014 response criteria, as assessed by the investigator, or death due to any cause, whichever occurred first.

    Time frame: From the date of first documented response of CR or PR to the first documented PD or death from any cause, whichever occurred first (maximum up to 50 months)

  5. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily have a causal relationship with this treatment. TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of brentuximab vedotin or lenalidomide or 110 days after last dose of rituximab, whichever was later. AEs included both serious AE (SAEs) and all other AEs. An AE was classified as an SAE if it met one of the following criteria: fatal, life threatening, required or prolonged hospitalization, disabling/ incapacitating, congenital anomaly or birth defect, medically significant.

    Time frame: From first dose of study treatment (Day 1) up to 30 days after last dose of brentuximab vedotin or lenalidomide or 110 days after last dose of rituximab, whichever was later (maximum up to 50 months)

  6. Number of Participants With TEAEs Based on Maximum Severity

    An AE was any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily have a causal relationship with this treatment. TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of brentuximab vedotin or lenalidomide or 110 days after last dose of rituximab, whichever was later. AE severity graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version (v) 5.0 where, grade 1=mild AE; grade 2=moderate AE; grade 3=severe AE; grade 4= life-threatening; urgent intervention indicated; and grade 5= death related to AE.

    Time frame: From first dose of study treatment (Day 1) up to 30 days after last dose of brentuximab vedotin or lenalidomide or 110 days after last dose of rituximab, whichever was later (maximum up to 50 months)

  7. Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs)

    TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of brentuximab vedotin or lenalidomide or 110 days after last dose of rituximab, whichever was later. An AE was classified as an SAE if it met one of the following criteria: fatal, life threatening, required or prolonged hospitalization, disabling/ incapacitating, congenital anomaly or birth defect, medically significant.

    Time frame: From first dose of study treatment (Day 1) up to 30 days after last dose of brentuximab vedotin or lenalidomide or 110 days after last dose of rituximab, whichever was later (maximum up to 50 months)

  8. Number of Participants With TEAEs: Through Study Completion Date

    An AE was any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily had a causal relationship with this treatment. TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of brentuximab vedotin or lenalidomide or 110 days after last dose of rituximab, whichever was later. AEs included both SAEs and all other AEs.

    Time frame: From first dose of study treatment (Day 1) through study completion

  9. Number of Participants With TEAEs Based on Maximum Severity: Through Study Completion Date

    An AE was any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily had a causal relationship with this treatment. TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of brentuximab vedotin or lenalidomide or 110 days after last dose of rituximab, whichever was later. AE severity graded using the NCI-CTCAE v 5.0 where, grade 1=mild AE; grade 2=moderate AE; grade 3=severe AE; grade 4= life-threatening; urgent intervention indicated; and grade 5= death related to AE.

    Time frame: From first dose of study treatment (Day 1) through study completion

  10. Number of Participants With TESAEs: Through Study Completion Date

    TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of brentuximab vedotin or lenalidomide or 110 days after last dose of rituximab, whichever was later. An AE was classified as an SAE if it met one of the following criteria: fatal, life threatening, required or prolonged hospitalization, disabling/ incapacitating, congenital anomaly or birth defect, medically significant.

    Time frame: From first dose of study treatment (Day 1) through study completion

  11. OS in Cluster of Differentiation 30 (CD30)-Positive Participants

    OS was defined as the time from the date of randomization to the date of death due to any cause. OS was evaluated in participants with CD30 expression status using a predefined cutoff of \>= 1%. Participants with CD30 tumor expression \>= 1% were classified as CD30-positive. CD30 positivity was defined as \>=1% of target lymphoid cells demonstrating membrane, cytoplasmic, and/or Golgi staining for CD30 at any intensity above background staining, as determined relative to the corresponding negative control. Participants who had not died were censored at the last known alive date or the data cutoff date, whichever was earlier.

    Time frame: From the date of randomization until date of death or censoring date, whichever occurred first (maximum up to 50 months)

07

Results

Posted Oct 21, 2026

Participant flow

A total of 240 participants were enrolled in the study. Of these,10 participants were excluded as these participants were part of the Safety Run-In population prior to the random assignment stage of the trial, therefore they are excluded from the ITT population. Data for these 10 participants were not provided in any of the section of the result.

Participant flow — Overall Study
MilestoneBrentuximab Vedotin + Lenalidomide + RituximabPlacebo + Lenalidomide + Rituximab
Started112118
Intent-to-treat (itt) analysis set112118
Safety analysis set112116
Completed00
Not completed112118
Withdrew: Withdrawal by subject711
Withdrew: Death7383
Withdrew: Other3224

Outcome measures

PrimaryOverall Survival (OS)

OS was defined as the time from the date of randomization to the date of death due to any cause. Participants who had not died were censored at the last known alive date or the data cutoff date, whichever was earlier. OS was estimated using the Kaplan-Meier method.

Time frame:
From the date of randomization until date of death or censoring date, whichever occurred first (maximum up to 50 months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsBrentuximab Vedotin + Lenalidomide + RituximabPlacebo + Lenalidomide + Rituximab
Overall Survival (OS)14.8 (10.3 to 21.5)7.8 (5.7 to 11.7)
Statistical analysis
  • Brentuximab Vedotin + Lenalidomide + Rituximab vs Placebo + Lenalidomide + Rituximab · Log Rank · p = =0.0127 · Hazard ratio (hr): 0.68 · 95% CI 0.501 to 0.922Hazard ratio was calculated based on stratified Cox proportional hazards regression model.
SecondaryProgression-Free Survival (PFS) as Assessed by Investigator Per Lugano 2014

PFS was defined as the time from the date of randomization to the date of first documentation of progressive disease (PD) or to death due to any cause, whichever occurred first, based on the investigator assessment of tumor response according to the criteria defined by the Lugano Classification, 2014.

Time frame:
From date of randomization until the first documentation of PD or to death due to any cause, whichever occurred first (maximum up to 50 months)
Reported as:
Median · Months
Progression-Free Survival (PFS) as Assessed by Investigator Per Lugano 2014
MonthsBrentuximab Vedotin + Lenalidomide + RituximabPlacebo + Lenalidomide + Rituximab
Progression-Free Survival (PFS) as Assessed by Investigator Per Lugano 20144.2 (3.0 to 7.1)2.6 (1.4 to 3.1)
Statistical analysis
  • Brentuximab Vedotin + Lenalidomide + Rituximab vs Placebo + Lenalidomide + Rituximab · Log Rank · p = =0.0012 · Hazard ratio (hr): 0.607 · 95% CI 0.447 to 0.824Hazard ratio was calculated based on stratified Cox proportional hazards regression model.
SecondaryObjective Response Rate (ORR) as Assessed by Investigator Per Lugano 2014

ORR per Lugano 2014 by investigator was defined as the percentage of participants with a response assessment of complete response (CR) or partial response (PR) per the Lugano 2014 response criteria as assessed by the investigator.

Time frame:
From the date of randomization until PD or initiation of new anticancer therapy (maximum up to 50 months)
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) as Assessed by Investigator Per Lugano 2014
Percentage of participantsBrentuximab Vedotin + Lenalidomide + RituximabPlacebo + Lenalidomide + Rituximab
Objective Response Rate (ORR) as Assessed by Investigator Per Lugano 201464.3 (54.7 to 73.1)41.5 (32.5 to 51.0)
Statistical analysis
  • Brentuximab Vedotin + Lenalidomide + Rituximab vs Placebo + Lenalidomide + Rituximab · Cochran-Mantel-Haenszel · p = =0.0006
SecondaryComplete Response (CR) Rate as Assessed by Investigator Per Lugano 2014

CR rate per Lugano 2014 by investigator was defined as the percentage of participants with a best response of CR per the Lugano 2014 response criteria as assessed by the investigator.

Time frame:
From the date of randomization until PD or initiation of new anticancer therapy (maximum up to 50 months)
Reported as:
Number · Percentage of participants
Complete Response (CR) Rate as Assessed by Investigator Per Lugano 2014
Percentage of participantsBrentuximab Vedotin + Lenalidomide + RituximabPlacebo + Lenalidomide + Rituximab
Complete Response (CR) Rate as Assessed by Investigator Per Lugano 201441.1 (31.9 to 50.8)18.6 (12.1 to 26.9)
SecondaryDuration of Response (DOR) as Assessed by Investigator Per Lugano 2014

DOR was defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of tumor progression per the Lugano 2014 response criteria, as assessed by the investigator, or death due to any cause, whichever occurred first.

Time frame:
From the date of first documented response of CR or PR to the first documented PD or death from any cause, whichever occurred first (maximum up to 50 months)
Reported as:
Median · Months
Duration of Response (DOR) as Assessed by Investigator Per Lugano 2014
MonthsBrentuximab Vedotin + Lenalidomide + RituximabPlacebo + Lenalidomide + Rituximab
Duration of Response (DOR) as Assessed by Investigator Per Lugano 20148.3 (4.1 to 15.3)4.1 (2.8 to 8.1)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily have a causal relationship with this treatment. TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of brentuximab vedotin or lenalidomide or 110 days after last dose of rituximab, whichever was later. AEs included both serious AE (SAEs) and all other AEs. An AE was classified as an SAE if it met one of the following criteria: fatal, life threatening, required or prolonged hospitalization, disabling/ incapacitating, congenital anomaly or birth defect, medically significant.

Time frame:
From first dose of study treatment (Day 1) up to 30 days after last dose of brentuximab vedotin or lenalidomide or 110 days after last dose of rituximab, whichever was later (maximum up to 50 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsBrentuximab Vedotin + Lenalidomide + RituximabPlacebo + Lenalidomide + Rituximab
Number of Participants With Treatment Emergent Adverse Events (TEAEs)109113
SecondaryNumber of Participants With TEAEs Based on Maximum Severity

An AE was any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily have a causal relationship with this treatment. TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of brentuximab vedotin or lenalidomide or 110 days after last dose of rituximab, whichever was later. AE severity graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version (v) 5.0 where, grade 1=mild AE; grade 2=moderate AE; grade 3=severe AE; grade 4= life-threatening; urgent intervention indicated; and grade 5= death related to AE.

Time frame:
From first dose of study treatment (Day 1) up to 30 days after last dose of brentuximab vedotin or lenalidomide or 110 days after last dose of rituximab, whichever was later (maximum up to 50 months)
Reported as:
Count of participants · Participants
Number of Participants With TEAEs Based on Maximum Severity
ParticipantsBrentuximab Vedotin + Lenalidomide + RituximabPlacebo + Lenalidomide + Rituximab
Grade 115
Grade 2917
Grade 34551
Grade 43831
Grade 5169
SecondaryNumber of Participants With Treatment Emergent Serious Adverse Events (TESAEs)

TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of brentuximab vedotin or lenalidomide or 110 days after last dose of rituximab, whichever was later. An AE was classified as an SAE if it met one of the following criteria: fatal, life threatening, required or prolonged hospitalization, disabling/ incapacitating, congenital anomaly or birth defect, medically significant.

Time frame:
From first dose of study treatment (Day 1) up to 30 days after last dose of brentuximab vedotin or lenalidomide or 110 days after last dose of rituximab, whichever was later (maximum up to 50 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs)
ParticipantsBrentuximab Vedotin + Lenalidomide + RituximabPlacebo + Lenalidomide + Rituximab
Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs)7359
SecondaryNumber of Participants With TEAEs: Through Study Completion Date

An AE was any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily had a causal relationship with this treatment. TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of brentuximab vedotin or lenalidomide or 110 days after last dose of rituximab, whichever was later. AEs included both SAEs and all other AEs.

Time frame:
From first dose of study treatment (Day 1) through study completion

Results for this outcome have not been posted.

SecondaryNumber of Participants With TEAEs Based on Maximum Severity: Through Study Completion Date

An AE was any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily had a causal relationship with this treatment. TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of brentuximab vedotin or lenalidomide or 110 days after last dose of rituximab, whichever was later. AE severity graded using the NCI-CTCAE v 5.0 where, grade 1=mild AE; grade 2=moderate AE; grade 3=severe AE; grade 4= life-threatening; urgent intervention indicated; and grade 5= death related to AE.

Time frame:
From first dose of study treatment (Day 1) through study completion

Results for this outcome have not been posted.

SecondaryNumber of Participants With TESAEs: Through Study Completion Date

TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of brentuximab vedotin or lenalidomide or 110 days after last dose of rituximab, whichever was later. An AE was classified as an SAE if it met one of the following criteria: fatal, life threatening, required or prolonged hospitalization, disabling/ incapacitating, congenital anomaly or birth defect, medically significant.

Time frame:
From first dose of study treatment (Day 1) through study completion

Results for this outcome have not been posted.

SecondaryOS in Cluster of Differentiation 30 (CD30)-Positive Participants

OS was defined as the time from the date of randomization to the date of death due to any cause. OS was evaluated in participants with CD30 expression status using a predefined cutoff of \>= 1%. Participants with CD30 tumor expression \>= 1% were classified as CD30-positive. CD30 positivity was defined as \>=1% of target lymphoid cells demonstrating membrane, cytoplasmic, and/or Golgi staining for CD30 at any intensity above background staining, as determined relative to the corresponding negative control. Participants who had not died were censored at the last known alive date or the data cutoff date, whichever was earlier.

Time frame:
From the date of randomization until date of death or censoring date, whichever occurred first (maximum up to 50 months)
Reported as:
Median · Months
OS in Cluster of Differentiation 30 (CD30)-Positive Participants
MonthsBrentuximab Vedotin + Lenalidomide + RituximabPlacebo + Lenalidomide + Rituximab
OS in Cluster of Differentiation 30 (CD30)-Positive Participants14.2 (7.1 to 39.4)8.8 (6.0 to 24.4)

Adverse events

Collected over SAEs and other AEs: From first dose of study treatment (Day 1) up to 30 days after last dose of brentuximab vedotin or lenalidomide or 110 days after last dose of rituximab, whichever was later (maximum up to 50 months)'. All cause mortality: From the date of randomization until date of death or censoring date, whichever occurred first (maximum up to 50 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brentuximab Vedotin + Lenalidomide + Rituximab78/112 (69.6%)73/112 (65.2%)105/112 (93.8%)
Placebo + Lenalidomide + Rituximab92/118 (78%)59/116 (50.9%)101/116 (87.1%)
Most frequent serious events
Showing 10 of 137
Most frequent serious events
EventBrentuximab Vedotin + Lenalidomide + RituximabPlacebo + Lenalidomide + Rituximab
PneumoniaInfections and infestations14/1128/116
COVID-19Infections and infestations9/1126/116
COVID-19 pneumoniaInfections and infestations8/1125/116
Febrile neutropeniaBlood and lymphatic system disorders7/1127/116
General physical health deteriorationGeneral disorders5/1123/116
PyrexiaGeneral disorders3/1125/116
Septic shockInfections and infestations4/1121/116
Urinary tract infectionInfections and infestations4/1120/116
Acute kidney injuryRenal and urinary disorders2/1124/116
ThrombocytopeniaBlood and lymphatic system disorders3/1121/116
Most frequent other events
Showing 10 of 45
Most frequent other events
EventBrentuximab Vedotin + Lenalidomide + RituximabPlacebo + Lenalidomide + Rituximab
NeutropeniaBlood and lymphatic system disorders53/11239/116
ThrombocytopeniaBlood and lymphatic system disorders39/11228/116
DiarrhoeaGastrointestinal disorders37/11229/116
AnaemiaBlood and lymphatic system disorders35/11233/116
FatigueGeneral disorders28/11221/116
AstheniaGeneral disorders25/11216/116
Peripheral sensory neuropathyNervous system disorders24/1129/116
ConstipationGastrointestinal disorders21/11223/116
PyrexiaGeneral disorders21/11214/116
COVID-19Infections and infestations21/11215/116

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Brentuximab Vedotin + Lenalidomide + RituximabPlacebo + Lenalidomide + RituximabTotal
Mean69.2 ± 12.765.8 ± 14.567.4 ± 13.8
Sex: Female, Male
Sex: Female, Male(Participants)Brentuximab Vedotin + Lenalidomide + RituximabPlacebo + Lenalidomide + RituximabTotal
Female5248100
Male6070130
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Brentuximab Vedotin + Lenalidomide + RituximabPlacebo + Lenalidomide + RituximabTotal
Ethnicity — Hispanic, Latino/a, or of Spanish Origin459
Ethnicity — Not of Hispanic, Latino/a, or Spanish Origin9084174
Ethnicity — Unknown011
Ethnicity — Not Reportable182846
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Brentuximab Vedotin + Lenalidomide + RituximabPlacebo + Lenalidomide + RituximabTotal
Race — American Indian or Alaska Native011
Race — Asian283260
Race — White6556121
Race — Other011
Race — Unknown101
Race — Not Reported182846
08

Study locations

143 sites

Showing the first 100 of 143 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Bartlett NL, Hahn U, Kim WS, Fleury I, Laribi K, Bergua JM, Bouabdallah K, Forward N, Bijou F, MacDonald D, Portell CA, Ghesquieres H, Nowakowski G, Yasenchak CA, Patterson M, Ho L, Rustia E, Fanale M, Jie F, Kim JA. Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2025 Mar 20;43(9):1061-1072. doi: 10.1200/JCO-24-02242. Epub 2025 Jan 7. PubMed 39772655 ↗
  • Ward JP, Berrien-Elliott MM, Gomez F, Luo J, Becker-Hapak M, Cashen AF, Wagner-Johnston ND, Maddocks K, Mosior M, Foster M, Krysiak K, Schmidt A, Skidmore ZL, Desai S, Watkins MP, Fischer A, Griffith M, Griffith OL, Fehniger TA, Bartlett NL. Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma. Blood. 2022 Mar 31;139(13):1999-2010. doi: 10.1182/blood.2021011894. PubMed 34780623 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Jan 2026, 65 months.

Results were first posted in Oct 2026, 8 months after primary completion.

Of 37 industry-sponsored phase 3 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 82. This study's 65 months is above that.

Counting every sponsor, half of 73 studies reached it within 57 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2020
First posted
May 27, 2020
StartActual
Aug 20, 2020
Primary completionActual
Jan 23, 2026
CompletionEst.
Dec 31, 2026
Results first posted
Oct 21, 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 21, 2026
Enrollment
239→240
Oct 21, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedOverall survivalSurvival (OS)Time frame: Approximately 2 years → From the date of randomization until date of death or censoring date, whichever occurred first (maximum up to 50 months)
Oct 21, 2026
Documents
Secondary outcomes
4 edited, 7 added, 2 removed
What changed in the outcomes
  • EditedProgression-free survivalFree Survival (PFS) as Assessed by Investigator Per Lugano 2014Time frame: Approximately 1 year → From date of randomization until the first documentation of PD or to death due to any cause, whichever occurred first (maximum up to 50 months)
  • EditedObjective response rateResponse Rate (ORR) as Assessed by Investigator Per Lugano 2014Time frame: Approximately 1 year → From the date of randomization until PD or initiation of new anticancer therapy (maximum up to 50 months)
  • EditedComplete responseResponse (CR) rateRate as Assessed by Investigator Per Lugano 2014Time frame: Approximately 1 year → From the date of randomization until PD or initiation of new anticancer therapy (maximum up to 50 months)
  • EditedDuration of responseResponse (DOR) as Assessed by Investigator Per Lugano 2014Time frame: Approximately 1 year → From the date of first documented response of CR or PR to the first documented PD or death from any cause, whichever occurred first (maximum up to 50 months)
  • AddedNumber of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: From first dose of study treatment (Day 1) up to 30 days after last dose of brentuximab vedotin or lenalidomide or 110 days after last dose of rituximab, whichever was later (maximum up to 50 months)
  • AddedNumber of Participants With TEAEs Based on Maximum SeverityTime frame: From first dose of study treatment (Day 1) up to 30 days after last dose of brentuximab vedotin or lenalidomide or 110 days after last dose of rituximab, whichever was later (maximum up to 50 months)
  • AddedNumber of Participants With Treatment Emergent Serious Adverse Events (TESAEs)Time frame: From first dose of study treatment (Day 1) up to 30 days after last dose of brentuximab vedotin or lenalidomide or 110 days after last dose of rituximab, whichever was later (maximum up to 50 months)
  • AddedNumber of Participants With TEAEs: Through Study Completion DateTime frame: From first dose of study treatment (Day 1) through study completion
  • AddedNumber of Participants With TEAEs Based on Maximum Severity: Through Study Completion DateTime frame: From first dose of study treatment (Day 1) through study completion
  • AddedNumber of Participants With TESAEs: Through Study Completion DateTime frame: From first dose of study treatment (Day 1) through study completion
  • AddedOS in Cluster of Differentiation 30 (CD30)-Positive ParticipantsTime frame: From the date of randomization until date of death or censoring date, whichever occurred first (maximum up to 50 months)
  • RemovedIncidence of adverse eventsTime frame: Approximately 1 year
  • RemovedOS in CD30+ participantsTime frame: Approximately 2 years
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Results posted
    Enrollment 239→240
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedOverall survivalSurvival (OS)Time frame: Approximately 2 years → From the date of randomization until date of death or censoring date, whichever occurred first (maximum up to 50 months)
    Secondary outcomes 4 edited, 7 added, 2 removed
    What changed in the outcomes
    • EditedProgression-free survivalFree Survival (PFS) as Assessed by Investigator Per Lugano 2014Time frame: Approximately 1 year → From date of randomization until the first documentation of PD or to death due to any cause, whichever occurred first (maximum up to 50 months)
    • EditedObjective response rateResponse Rate (ORR) as Assessed by Investigator Per Lugano 2014Time frame: Approximately 1 year → From the date of randomization until PD or initiation of new anticancer therapy (maximum up to 50 months)
    • EditedComplete responseResponse (CR) rateRate as Assessed by Investigator Per Lugano 2014Time frame: Approximately 1 year → From the date of randomization until PD or initiation of new anticancer therapy (maximum up to 50 months)
    • EditedDuration of responseResponse (DOR) as Assessed by Investigator Per Lugano 2014Time frame: Approximately 1 year → From the date of first documented response of CR or PR to the first documented PD or death from any cause, whichever occurred first (maximum up to 50 months)
    • AddedNumber of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: From first dose of study treatment (Day 1) up to 30 days after last dose of brentuximab vedotin or lenalidomide or 110 days after last dose of rituximab, whichever was later (maximum up to 50 months)
    • AddedNumber of Participants With TEAEs Based on Maximum SeverityTime frame: From first dose of study treatment (Day 1) up to 30 days after last dose of brentuximab vedotin or lenalidomide or 110 days after last dose of rituximab, whichever was later (maximum up to 50 months)
    • AddedNumber of Participants With Treatment Emergent Serious Adverse Events (TESAEs)Time frame: From first dose of study treatment (Day 1) up to 30 days after last dose of brentuximab vedotin or lenalidomide or 110 days after last dose of rituximab, whichever was later (maximum up to 50 months)
    • AddedNumber of Participants With TEAEs: Through Study Completion DateTime frame: From first dose of study treatment (Day 1) through study completion
    • AddedNumber of Participants With TEAEs Based on Maximum Severity: Through Study Completion DateTime frame: From first dose of study treatment (Day 1) through study completion
    • AddedNumber of Participants With TESAEs: Through Study Completion DateTime frame: From first dose of study treatment (Day 1) through study completion
    • AddedOS in Cluster of Differentiation 30 (CD30)-Positive ParticipantsTime frame: From the date of randomization until date of death or censoring date, whichever occurred first (maximum up to 50 months)
    • RemovedIncidence of adverse eventsTime frame: Approximately 1 year
    • RemovedOS in CD30+ participantsTime frame: Approximately 2 years
    + 4 other changes: index terms, identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04404283
Responsible party
Sponsor
First posted
May 27, 2020
Start date
Aug 20, 2020
Primary completion
Jan 23, 2026
Completion
Dec 31, 2026 (estimated)
Results posted
Oct 21, 2026
Last update
Oct 21, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brentuximab Vedotin

Start the discussion